HCC
Conditions
Interventions
control group:Basic treatment + TACE
Test group:Basic treatment + TACE + Bezoar cultured in vitro
Sponsors
Changhai Hospital, Navy Military Medical University, Shanghai
Eligibility
Sex/Gender
All
Age
18 Years to 85 Years
Inclusion criteria
Inclusion criteria: 1. HCC diagnosed as unresectable according to the imaging technology and/or biopsy guidelines of the Diagnostic and Treatment Guidelines for Primary Liver Cancer (2022) 2. Unable or unwilling to accept palliative surgery, with at least one measurable lesion, and willing to accept TACE treatment 3. Barcelona stage: BCLC-B or C 4. Child-Pugh A5-B7 5. Age: 18-75 6. Within 1 week before enrollment, the performance score of the Eastern Cancer Cooperation Group (ECOG) was 0-1 7. Good organ and bone marrow function: (1) Hemoglobin >= 9.0g/dL (2) White blood cell count >= 3.0 x 10^9/ µ L (3) Platelet count >= 75 x 10^9/ µ L (4) Total bilirubin = 2.8g/dL (7) International normalized ratio (INR) = 30mL/min 8. The expected survival period is more than 12 weeks. 9. Voluntarily accept the treatment of this study protocol and sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Complicated with heart, brain, kidney, lung and other organ diseases; 2. The formation of tumor thrombus in the main portal vein, tumor thrombus in the bile duct and collateral vessels were less; 3. Severe varices of gastric fundus and esophageal and cardiac veins, severe portal hypertension, and risk of rupture and bleeding; 4. Systemic infection sepsis, liver abscess; 5. Liver function was classified as Grade C by Childpugh; 6. Abnormal liver function caused by severe cirrhosis, or obvious ascites and jaundice; 7. Tumor accounts for 70% or more of the whole liver; 8. Allergic constitution, or allergy to the drugs involved in this study; 9. Subjects have received any bezoar medication within two weeks before enrollment; 10. Have a history of other anti-tumor drugs or anti-tumor non-drug treatment in the past month.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Objective efficacy index;Inflammatory indicators;Biochemical index; | — |
Secondary
| Measure | Time frame |
|---|---|
| Progression-free survival; | — |
Countries
China
Contacts
Public ContactZhai Xiaofeng
Changhai Hospital, Navy Military Medical University, Shanghai
Outcome results
None listed